瑞图西马布作为唯一的类固醇节约剂在一般化肌痛性肌痛症:长期的结果
Zinovia-Maria Kefalopoulou1,2, Dimitra Veltsista3,4, Alexandra Germeni3
1Department of Neurology, University Hospital of Patras, 26504, Patras, Rio, Greece. zkefalopoulou@gmail.com.
概括
利图西马布有效治疗各种血清型的耐火性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛性肌痛 抗MuSK+患者经历了最大的好处,证明了修复药.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 瑞图西马布是一种B细胞耗尽单克隆抗体,是耐火性肌痛性硬性肌痛症 (MG) 的一种选择.
- 它的有效性已在抗MuSK+ MG中确立,但在抗AChR+和DSN MG中不太清楚.
- 这项研究评估了Rituximab在各种MG血清型中的长期有效性和安全性.
研究的目的:
- 评估Rituximab在耐火性泛性MG患者的长期有效性.
- 为了比较Rituximab在不同MG血清型 (anti-AChR+,anti-MuSK+,DSN) 的疗效.
- 为了评估与rituximab治疗相关的安全性,类固醇缓解效果和复发率.
主要方法:
- 一项开放性研究包括了患有一般性耐火性MG (抗AChR+,DSN) 或抗MuSK+MG的成年人.
- 选择了接受Rituximab的>12个月随访的患者.
- 主要结局:定量肌痛严重症 (QMG) 评分的变化;次要结局:安全性,类固醇使用,复发率.
主要成果:
- 30名患者 (16名抗AChR+,6名抗MuSK+,8名DSN) 接受了平均33.3个月的随访.
- 平均QMG得分 (11至4.3,p<0.001) 和复发率 (1.9至0.3/患者/年) 的显著下降.
- 93.1%的患者获得每日类固醇剂量≤10毫克;抗MuSK+患者显示出最大的益处. 没有发生危机或死亡.
结论:
- 利图西马布在耐火抗AChR+和DSN MG.中有效且耐受性良好.
- 抗MuSK+ MG 患者经历了利图西马布治疗的最显著益处.
- 利图西马布表现出有利的长期安全性,具有显著的类固醇节约作用.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
173
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
173
01:15Myasthenia Gravis: Diagnostic Tests
929
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
929
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
136
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
136
01:14Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
150
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
150